Get started
Author

Keith William Orford

Observed names: K. Orford, K. W. Orford, KW Orford, Keith Orford, Keith W. Orford, Keith W. Orford
Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Memorial Sloan Kettering Cancer Center, Harvard University, Emory University, University of California, San Francisco, Georgetown University, GlaxoSmithKline (United Kingdom), Georgetown University Medical Center, Massachusetts General Hospital, Angeles Clinic and Research Institute, GlaxoSmithKline (United States), Calithera (United States), HealthONE, Tagworks Pharmaceuticals (Netherlands), Tennessee Oncology, Harvard Stem Cell Institute, UCSF Helen Diller Family Comprehensive Cancer Center, FogPharma (United States), Georgetown Lombardi Comprehensive Cancer Center, Columbia University, University of Pennsylvania, Stanford University
OpenAlex ID: A5109262452
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation
2008 · Keith W. Orford, David T. Scadden · Nature Reviews Genetics · 851
Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin
1997 · Keith Orford, Caroline Crockett, et al. · Journal of Biological Chemistry · 715
PDF
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015 · Ryan B. Corcoran, Chloe E. Atreya, et al. · Journal of Clinical Oncology · 508
PDF
Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-Independent Growth, Anoikis, and Radiation-Induced Cell Cycle Arrest
1999 · Keith Orford, Caroline C. Orford, et al. · The Journal of Cell Biology · 276
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma
2022 · Nizar M. Tannir, Neeraj Agarwal, et al. · JAMA Oncology · 155
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
2014 · Anthony W. Tolcher, Amita Patnaik, et al. · Cancer Chemotherapy and Pharmacology · 154
Differential H3K4 Methylation Identifies Developmentally Poised Hematopoietic Genes
2008 · Keith Orford, Peter Kharchenko, et al. · Developmental Cell · 154
PDF
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
2022 · Chung-Han Lee, Robert Motzer, et al. · Clinical Cancer Research · 114
PDF
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
2021 · James J. Harding, Melinda Telli, et al. · Clinical Cancer Research · 94
Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).
2014 · Igor Puzanov, Margaret K. Callahan, et al. · Journal of Clinical Oncology · 92
Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
2014 · Johanna C. Bendell, Chloe Evelyn Atreya, et al. · Journal of Clinical Oncology · 63
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).
2015 · Chloe Evelyn Atreya, Eric Van Cutsem, et al. · Journal of Clinical Oncology · 62
Genome-wide Map of Nuclear Protein Degradation Shows NCoR1 Turnover as a Key to Mitochondrial Gene Regulation
2013 · André Catic, Carol Y. Suh, et al. · Cell · 51
PDF
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
2013 · Lot A. Devriese, Kevin M. Koch, et al. · Investigational New Drugs · 48
CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors.
2017 · Kyriakos P. Papadopoulos, Frank Yung-Chin Tsai, et al. · Journal of Clinical Oncology · 47
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours
2014 · Cathrine Leonowens, Carolyn Pendry, et al. · British Journal of Clinical Pharmacology · 47
Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia
2015 · Eunice S. Wang, Olga Frankfurt, et al. · Blood · 44
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.
2021 · Nizar M. Tannir, Neeraj Agarwal, et al. · Journal of Clinical Oncology · 41
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).
2016 · Funda Meric-Bernstam, Nizar M. Tannir, et al. · Journal of Clinical Oncology · 39
Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.
2014 · Ryan Bruce Corcoran, Chloe Evelyn Atreya, et al. · Journal of Clinical Oncology · 32
Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma
2015 · Dan T. Vogl, Anas Younes, et al. · Blood · 29
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).
2016 · Angela DeMichele, James J. Harding, et al. · Journal of Clinical Oncology · 28
Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer
2013 · Donna S. Cox, Kyri Papadopoulos, et al. · The Journal of Clinical Pharmacology · 28
Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers
2013 · May Y. K. Ho, Michael J. Morris, et al. · Xenobiotica · 26
A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
2024 · Kyriakos P. Papadopoulos, Jordi Rodon Ahnert, et al. · Journal of Clinical Oncology · 13
Works count: 72
Citation count: 3,827
H-index: 24
I10-index: 30
Year
Topic
Type